This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. A few years back, TIGIT was hailed as the ...

Chimeric antigen receptor (CAR) T Cell therapy has emerged as a promising immunotherapeutic approach to treat blood cancers, even leading to long-lasting remission for some advanced cases. The FDA has ...

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. Like PD-L1, TIGIT is thought to ...

Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to fight cancer, potentially paving the way for new treatments. In a recent ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. This is the online edition of ESMO ...

Dublin, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The "Anti TIGIT Antibody Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. The report provides ...

Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022" report has been added to ResearchAndMarkets.com's offering. T-cell ...

Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos Therapeutics after the failure of its GSK-partnered TIGIT drug led the company ...

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene. The ...

- Arcus will host a conference call today, Wednesday, June 23, 2021 at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time to provide an update on its ongoing domvanalimab program HAYWARD, Calif.--(BUSINESS ...

Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response ...

Immune checkpoints have a vital role in controlling the duration and magnitude of an immune response. When immune checkpoints work as they should, a suitable response to insults like infection and ...